- Home
- FDSB vs IFRX Comparison
FDSB vs IFRX Comparison
Compare FDSB & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDSB
- IFRX
- Stock Information
- Founded
- FDSB 1926
- IFRX 2007
- Country
- FDSB United States
- IFRX Germany
- Employees
- FDSB N/A
- IFRX N/A
- Industry
- FDSB
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- FDSB
- IFRX Health Care
- Exchange
- FDSB NYSE
- IFRX Nasdaq
- Market Cap
- FDSB 68.9M
- IFRX 65.8M
- IPO Year
- FDSB N/A
- IFRX 2017
- Fundamental
- Price
- FDSB $12.61
- IFRX $1.69
- Analyst Decision
- FDSB
- IFRX Strong Buy
- Analyst Count
- FDSB 0
- IFRX 4
- Target Price
- FDSB N/A
- IFRX $8.50
- AVG Volume (30 Days)
- FDSB 3.9K
- IFRX 262.5K
- Earning Date
- FDSB 05-13-2025
- IFRX 05-07-2025
- Dividend Yield
- FDSB N/A
- IFRX N/A
- EPS Growth
- FDSB N/A
- IFRX N/A
- EPS
- FDSB 0.02
- IFRX N/A
- Revenue
- FDSB $12,612,000.00
- IFRX $140,242.00
- Revenue This Year
- FDSB N/A
- IFRX $61.96
- Revenue Next Year
- FDSB N/A
- IFRX $80.59
- P/E Ratio
- FDSB $538.70
- IFRX N/A
- Revenue Growth
- FDSB 40.41
- IFRX 30.90
- 52 Week Low
- FDSB $9.85
- IFRX $0.82
- 52 Week High
- FDSB $14.50
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- FDSB N/A
- IFRX 62.40
- Support Level
- FDSB N/A
- IFRX $1.53
- Resistance Level
- FDSB N/A
- IFRX $1.92
- Average True Range (ATR)
- FDSB 0.00
- IFRX 0.19
- MACD
- FDSB 0.00
- IFRX 0.02
- Stochastic Oscillator
- FDSB 0.00
- IFRX 74.59
About FDSB FIFTH DISTRICT BANCORP INC.
Fifth District Bancorp inc is a holding company of Fifth District. Fifth District portfolio consists primarily of fixed-rate one- to four-family residential mortgage loans also originate construction loans, home equity loans, home equity lines of credit, land loans, and share loans (loans secured by deposit accounts at Fifth District) and purchase commercial business loans. The company offer a variety of deposit accounts including checking accounts, money market accounts, and certificates of deposit. In addition, it offers electronic banking services including mobile banking, on-line banking, telephone banking, bill pay, and electronic funds transfer via SmartPay.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.